💉NEW: Phase 3 trial shows new non-vaccine way of preventing COVID provides significant reduction in infection & severe disease

✅ 77% reduction of symptomatic COVID
✅ No severe disease or death

💉1st use of long-acting antibody (LAAB) combination

📊 5,197 trial participants

💉 The trial is called PROVENT and is of a new LAAB combination made by AstraZeneca- it is called AZD7442

🦠 It’s the first monoclonal antibody combination used as pre-exposure prophylaxis used against COVID

🌍 Trials took place in 87 sites in:

🇬🇧 🇺🇸 🇫🇷 🇪🇸 🇧🇪

💉 5,197 people aged 18+ received either the the LAAB combination or a placebo

📉 In those that got the drug infection was reduced by 77% and no one got severe disease or died

🏥 More than 75% people had co-morbidities that can reduce immune response to vaccines

👴🏻 43% of people were aged over 60

🏥 75% had co-morbidities & other characteristics associated with an increased risk for severe COVID-19 should they become infected, including those with immunosuppressive disease or taking immunosuppressive medication etc

✅ AZ is now preparing to go to regulators to seek emergency use authorisation for the treatment

💉 It would be aimed at those for whom vaccines are less effective or not appropriate but would be given in a similar way

Myron Levin, Professor of Paediatrics & Medicine, University of Colorado School of Medicine & principal investigator:

“PROVENT data show one dose AZD7442, delivered in convenient intramuscular form, can quickly & effectively prevent symptomatic COVID-19….

…With these exciting results, AZD7442 could be an important tool in our arsenal to help people who may need more than a vaccine to return to their normal lives.”